Evidence analysisOctober 19, 2026Health & Science

Human medicines European public assessment report (EPAR): Iressa, gefitinib, Date of authorisation: 24/06/2009, Revision: 16, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

What is established

Iressa is a medicine whose active ingredient is gefitinib, primarily used to treat adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that harbors activating mutations in the epidermal growth factor receptor (EGFR) gene. It is administered orally, typically one 250 mg tablet once daily, and can be given under a doctor’s supervision experienced in anticancer therapies.

Gefitinib works as a protein-tyrosine-kinase inhibitor that blocks enzymes—tyrosine kinases—on cancer cells, including EGFR which promotes growth and spread of cancer. It specifically targets cancer cells with EGFR mutations, slowing down tumor progression.

The drug’s efficacy has been evaluated in controlled clinical trials. In one major study of 1,217 patients, Iressa delayed disease progression more effectively than a carboplatin-paclitaxel combination, especially in patients with the EGFR mutation (average progression-free survival of about 9.5 months versus 6 months). Another trial comparing Iressa to docetaxel showed similar overall survival among all patients.

Common side effects include appetite loss, gastrointestinal symptoms (diarrhea, nausea, vomiting), mouth inflammation, elevated liver enzymes, skin rash, and weakness. A rare but serious risk is interstitial lung disease. Iressa is contraindicated in breastfeeding mothers and those with hypersensitivity to gefitinib or excipients.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) assessed clinical data and concluded the benefits outweigh risks in the specified patient population. The European Commission authorized Iressa in the EU in June 2009, with ongoing updates to product information by 2023.

What the source claims

  • Iressa is authorized for use in the EU for treating NSCLC patients harboring EGFR mutations.
  • The medicine slows tumor growth by inhibiting EGFR-related signaling pathways.
  • It has been tested in large, comparative clinical trials demonstrating improved progression-free survival in mutation-positive patients.
  • Its safety profile includes mostly manageable side effects, but monitoring for rare lung toxicity is essential.
  • Approval decisions are based on thorough review of clinical study data and risk-benefit assessment by regulatory committees.

What may be missing from the usual framing

The evidence does not extensively detail long-term survival benefits beyond progression-free outcomes for mutation-positive patients, which remains a key factor in evaluating therapeutic value. Also, potential variations in effectiveness or safety among diverse demographic groups or those with comorbidities are not highlighted.

The source does not elaborate on the cost or accessibility of Iressa within healthcare systems, nor how these considerations may impact patient access or adherence. Additionally, it omits information on alternative therapies or how Iressa compares with emerging targeted treatments or immunotherapies in the same indication.

Competing evidence or uncertainty

The source summarizes evidence from two main clinical trials without detailing other studies that might include different patient populations or real-world data. While progression-free survival improved, overall survival benefits were not demonstrated against docetaxel across all patients, indicating some uncertainty about the long-term advantage for all users.

There may also be evolving scientific debate about the best sequence or combination of EGFR inhibitors with other agents in treatment regimens, which is not addressed. Potential drug resistance mechanisms and their clinical implications are not discussed.

In summary, additional evidence beyond these trials, including post-marketing surveillance and comparative effectiveness studies, would be needed to fully resolve such uncertainties.

Why it matters

Non-small-cell lung cancer is a common and often fatal disease. Targeted therapies like Iressa represent a shift from conventional chemotherapy toward treatments tailored to molecular characteristics of tumors, offering potentially improved outcomes and fewer side effects for selected patients.

Understanding the benefits and risks of gefitinib helps physicians make informed treatment decisions and supports regulatory and health system assessments of new cancer drugs. Transparency about evidence, limitations, and patient selection criteria is crucial in guiding appropriate clinical use and aligning expectations.

What to verify next

  • Updated clinical trial results or real-world data on long-term survival and quality of life outcomes in patients treated with Iressa.
  • Comparative assessments of gefitinib versus newer EGFR inhibitors or combination therapies for NSCLC.
  • Information on cost, reimbursement policies, and access disparities across different countries or regions.
  • Evidence regarding side effect management protocols and incidence rates of rare but serious risks such as interstitial lung disease.
  • Any new regulatory reviews or guideline updates related to Iressa use.

Readers are encouraged to consult the original European Medicines Agency source for comprehensive details and official documents regarding Iressa (gefitinib).

Source & verification

Primary source: What's new · October 19, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

Burkina Faso Targets Critics in Exile

Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…